JP2018186815A5 - - Google Patents

Download PDF

Info

Publication number
JP2018186815A5
JP2018186815A5 JP2018111489A JP2018111489A JP2018186815A5 JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5 JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5
Authority
JP
Japan
Prior art keywords
vlp
virus
protein
polynucleotide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018111489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018186815A (ja
JP6585237B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018186815A publication Critical patent/JP2018186815A/ja
Publication of JP2018186815A5 publication Critical patent/JP2018186815A5/ja
Application granted granted Critical
Publication of JP6585237B2 publication Critical patent/JP6585237B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018111489A 2012-03-26 2018-06-12 哺乳動物細胞へのパッケージングされたrnaの新規の送達 Active JP6585237B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615687P 2012-03-26 2012-03-26
US61/615,687 2012-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015503322A Division JP2015527296A (ja) 2012-03-26 2013-03-15 哺乳動物細胞へのパッケージングされたrnaの新規の送達

Publications (3)

Publication Number Publication Date
JP2018186815A JP2018186815A (ja) 2018-11-29
JP2018186815A5 true JP2018186815A5 (enExample) 2019-01-17
JP6585237B2 JP6585237B2 (ja) 2019-10-02

Family

ID=47998556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503322A Pending JP2015527296A (ja) 2012-03-26 2013-03-15 哺乳動物細胞へのパッケージングされたrnaの新規の送達
JP2018111489A Active JP6585237B2 (ja) 2012-03-26 2018-06-12 哺乳動物細胞へのパッケージングされたrnaの新規の送達

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015503322A Pending JP2015527296A (ja) 2012-03-26 2013-03-15 哺乳動物細胞へのパッケージングされたrnaの新規の送達

Country Status (5)

Country Link
US (3) US9506041B2 (enExample)
EP (2) EP3663395B1 (enExample)
JP (2) JP2015527296A (enExample)
AU (3) AU2013240248B2 (enExample)
WO (1) WO2013148302A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
EP3663395B1 (en) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Delivery of packaged rna to mammalian cells
WO2015095167A2 (en) 2013-12-16 2015-06-25 Chatterjee Deb K Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US11124775B2 (en) 2015-05-15 2021-09-21 Flash Therapeutics Retroviral particle comprising at least two encapsidated nonviral RNAs
FR3036118B1 (fr) * 2015-05-15 2019-07-12 Flash Therapeutics Particule retrovirale comportant au moins deux arn non viraux encapsides.
US20190002838A1 (en) 2015-06-19 2019-01-03 Seracare Life Sciences, Inc. Sindbis control virus
EP3341018A1 (en) 2015-08-28 2018-07-04 Wisconsin Alumni Research Foundation Generation of infectious influenza viruses from virus-like particles
WO2017083356A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
MX2019008143A (es) 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
US12178908B2 (en) 2018-02-26 2024-12-31 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
WO2020013317A1 (ja) * 2018-07-13 2020-01-16 国立大学法人京都大学 ウイルス様粒子及びその使用
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
US20220396806A1 (en) 2019-07-26 2022-12-15 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたhaを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
IL298128A (en) 2020-05-13 2023-01-01 Akouos Inc Compositions and methods for treating slc26a4-associated hearing loss
TW202208406A (zh) 2020-05-13 2022-03-01 美商阿科奧斯公司 用於治療kcnq4相關性聽力損失之組成物及方法
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
AU2021391433A1 (en) 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2024500786A (ja) 2020-12-29 2024-01-10 アコーオス インコーポレイテッド Clrn1関連難聴及び/または視力低下を治療するための組成物及び方法
WO2022261355A1 (en) 2021-06-09 2022-12-15 Chimeron Bio Corporation Self-amplifying rna-based vlp vaccines
US20240269265A1 (en) 2021-06-09 2024-08-15 Chimeron Bio Corporation Peptide VLP-Based Vaccines
AU2022356427A1 (en) 2021-09-30 2024-05-09 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CA3243517A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-VEGF Antibody Constructions and Related Methods for the Treatment of Symptoms Associated with Acoustic Neuroma
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same
CN121399470A (zh) 2023-05-03 2026-01-23 马尼福尔德生物技术有限公司 用于高通量蛋白质递送、筛选和检测的方法和组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004083A (en) 1911-01-09 1911-09-26 Henry Ritter Method of making sash-bars and die for forming same.
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
EP0817854A2 (en) 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US6902886B1 (en) 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
US20020052040A1 (en) 1999-06-30 2002-05-02 Nicholas Hunt Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US20080115199A1 (en) * 2001-12-06 2008-05-15 Albert Young Scheme for device and user authentication with key distribution in a wireless network
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
FR2862982B1 (fr) * 2003-12-02 2006-04-28 Genethon Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
WO2005115444A2 (en) 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
GB0426641D0 (en) 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
DE202006010918U1 (de) * 2006-07-14 2006-10-05 Flexi-Bogdahn Technik Gmbh & Co. Kg Leineneinrichtung für eine mechanisch auf- und abrollbare Leine zum Führen von Tieren
WO2008115199A2 (en) * 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
WO2009120883A2 (en) * 2008-03-26 2009-10-01 Life Technologies Corporation Virus-like particle mediated cellular delivery
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CN102753582A (zh) * 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
EP3663395B1 (en) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Delivery of packaged rna to mammalian cells
WO2015095167A2 (en) 2013-12-16 2015-06-25 Chatterjee Deb K Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon

Similar Documents

Publication Publication Date Title
JP2018186815A5 (enExample)
JP6585237B2 (ja) 哺乳動物細胞へのパッケージングされたrnaの新規の送達
JP2015527296A5 (enExample)
CA2567254C (en) Tc-83-derived alphavirus vectors, particles and methods
JP5572144B2 (ja) 改良されたアルファウイルスレプリコンおよびヘルパー構築物
CA2410948C (en) Method for the purification of alphavirus replicon particles
JP2015522581A5 (enExample)
Tubulekas et al. Alphavirus expression vectors and their use as recombinant vaccines: a minireview
JP2010530245A5 (enExample)
US20040235133A1 (en) Large scale production of packaged alphavirus replicons
JP2017515509A (ja) ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
Atasheva et al. Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation
Lundstrom Alphaviruses as expression vectors
JP2024512808A (ja) Calr及びjak2t細胞受容体
Lundstrom The potential of self-amplifying RNA vaccines for infectious diseases and COVID-19
US20080118956A1 (en) Viral Particles Containing An Alphavirus-Derived Vector And Method For Preparing Said Viral Particle
US20050221493A1 (en) Recombinant virus production for the manufacturing of vaccines
Dorange et al. Vesicular stomatitis virus glycoprotein: a transducing coat for SFV‐based RNA vectors
Aranda et al. Recent patents on alphavirus protein expression and vector production
Suzuki Application of reverse genetics system to Chikungunya virus study
Zhu et al. Selection and characterization of packaging cell lines for XJ-160 virus
EP1590450A2 (en) Recombinant virus production for the manufacturing of vaccines
Polo et al. Sindbis virus-based vectors for the study of class I antigen presentation in vitro and in vivo
Yang et al. Construction of nervous necrosis virus (NNV) genome-based DNA replicon vectors for the delivery of foreign antigens
Wu-yang et al. Research on basis of reverse genetics system of a Sindbis-like virus XJ-160